The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C

Bibliography

• Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35
   PubMed Web of Science ®Google Scholar
• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;1:74-81
   Web of Science ®Google Scholar
• Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):30
   Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Pasquale G, et al. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepat Mon 2013;13:e8352
   PubMed Web of Science ®Google Scholar
• Gentile I, Scarano F, Celotti A, et al.Low Vitamin D. Levels Are Associated with the Presence of Serum Cryoglobulins in Patients with Chronic HCV Infection. In Vivo 2015;29:399-404
   PubMed Web of Science ®Google Scholar
• Fusco F, D’Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44
   PubMed Web of Science ®Google Scholar
• WHO. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71
   PubMed Web of Science ®Google Scholar
• Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015;7:1377-89
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-27
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77-87
   PubMed Web of Science ®Google Scholar
• Gray RR, Salemi M, Klenerman P, et al. A new evolutionary model for hepatitis C virus chronic infection. PLoS Pathog 2012;8:3
   Web of Science ®Google Scholar
• Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012;36:663-83
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6
   PubMed Web of Science ®Google Scholar
• Shulla A, Randall G. Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol 2012;2:725-32
   Web of Science ®Google Scholar
• Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11:482-96
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia G. A pill a day keeps HCV away. Lancet Infect Dis 2015;15:616-17
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 2014;23:1211-23
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23:561-71
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
   PubMed Web of Science ®Google Scholar
• Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. Jama 2014;312:631-40
   PubMed Web of Science ®Google Scholar
• EASL. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;21:00208-1
   Google Scholar
• Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama 2012;308:2584-93
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
   PubMed Web of Science ®Google Scholar
• Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39:478-87
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res 2005;25:283-5
   PubMed Web of Science ®Google Scholar
• Tosone G, Borgia G, Gentile I, et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007;44:167-9
   PubMed Web of Science ®Google Scholar
• Rosina F, Tosti ME, Borghesio E, et al. Pegylated interferon alpha plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. Dig Liver Dis 2014;46:826-32
   PubMedGoogle Scholar
• Chung RT, Gale MJr, Polyak SJ, et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology2008;47:306-20
   PubMedGoogle Scholar
• Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis 2015;60:1829-36
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
   PubMed Web of Science ®Google Scholar
• Bruno S, Bollani S, Zignego AL, et al. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. J Viral Hepat 2015;22:469-80
   PubMed Web of Science ®Google Scholar
• Shahid I, WH AL, Hafeez MH, et al. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol 2014;6:1-13
   Google Scholar
• Bartenschlager R, Penin F, Lohmann V, et al. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011;19:95-103
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
   PubMed Web of Science ®Google Scholar
• Gerold G, Pietschmann T. The HCV life cycle: in vitro tissue culture systems and therapeutic targets. Dig Dis 2014;32:525-37
   PubMed Web of Science ®Google Scholar
• Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 2011;1:68-77
   Web of Science ®Google Scholar
• Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. Embo J 1996;15:12-22
   PubMed Web of Science ®Google Scholar
• Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-13
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013;14:1161-70
   PubMed Web of Science ®Google Scholar
• Ago H, Adachi T, Yoshida A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 1999;7:1417-26
   PubMed Web of Science ®Google Scholar
• Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 1999;96:13034-9
   PubMed Web of Science ®Google Scholar
• Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004;85:3173-88
   PubMed Web of Science ®Google Scholar
• Delang L, Neyts J, Vliegen I, et al. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol 2013;369:289-320
   PubMed Web of Science ®Google Scholar
• Madela K, McGuigan C. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Future Med Chem 2012;4:625-50
   PubMed Web of Science ®Google Scholar
• Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs 2014;74:273-82
   PubMed Web of Science ®Google Scholar
• Gounder C. A better treatment for hepatitis C. The New Yorker, December 2013. Available from: www.newyorker.com/tech/elements/a-better-treatment-for-hepatitis-c [Last accessed 31 August 2013]
   Google Scholar
• Pharmasset Ltd. Modified fluorinated nucleoside analogues. WO2005003147A2; 2005
   Google Scholar
• Wang P, Chun BK, Rachakonda S, et al. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem 2009;74:6819-24
   PubMed Web of Science ®Google Scholar
• Peifer M, Berger R, Shurtleff VW, et al. A general and enantioselective approach to pentoses: a rapid synthesis of PSI-6130, the nucleoside core of sofosbuvir. J Am Chem Soc 2014;136:5900-3
   PubMed Web of Science ®Google Scholar
• Sofia MJ, Bao D, Chang W, et al. Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202-18
   PubMed Web of Science ®Google Scholar
• Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010;285:34337-47
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet 2015;31:31
   Google Scholar
• Herbst DAJr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013;22:527-36
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013;11:1269-79
   PubMed Web of Science ®Google Scholar
• Babusis D, Curry MP, Denning J, et al. Translational Studies to understand the mechanism of liver delivery by sofosbuvir. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington DC, USA, 2014
   Google Scholar
• Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2’-deoxy-2’-fluoro-2’-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010;54:3187-96
   PubMed Web of Science ®Google Scholar
• Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 2014;19:211-20
   PubMed Web of Science ®Google Scholar
• Hebner CM, Lee YJ, Han B, et al. In vitro pangenotypic and combination activity of sofosbuvir in stable replicon cell lines. Presented at 63th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA, USA, 2012
   Google Scholar
• Cholongitas E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 2014;27:331-7
   PubMedGoogle Scholar
• Lawitz E, Rodriguez-Torres M, Cornpropst MT, et al. The effect of hepatic impairment in the pharmacokinetics and antiviral activity of PSI- 7977 in hepatitis C infected subjects treated for several days. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; 2012
   Google Scholar
• Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; 2012
   Google Scholar
• Gane E, Robson RA, Bonacini M, et al. Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA; 2014
   Google Scholar
• Denning J, Cornpropst M, Flach SD, et al. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother 2013;57:1201-8
   PubMed Web of Science ®Google Scholar
• Lawitz E, Rodriguez-Torres M, Denning JM, et al. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother 2013;57:1209-17
   PubMed Web of Science ®Google Scholar
• Noell BC, Besur SV, deLemos AS. Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther 2015;9:2367-74
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013;58:663-8
   PubMed Web of Science ®Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-7
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama 2013;310:804-11
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77
   PubMed Web of Science ®Google Scholar
• Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Dig Liver Dis 2014;15:31
   Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001
   PubMed Web of Science ®Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56:3359-68
   PubMed Web of Science ®Google Scholar
• Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014;59:1666-74
   PubMed Web of Science ®Google Scholar
• Donaldson EF, Harrington PR, O’Rear JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015;61:56-65
   PubMed Web of Science ®Google Scholar
• Gordon S, Contai S, Tournee W. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase III studies. J Hepatol 2014;60:S361-522
   Google Scholar
• Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 2014;7:131-40
   PubMed Web of Science ®Google Scholar
• Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med 2014;7:387-98
   PubMedGoogle Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology 2015;62:25-30
   PubMed Web of Science ®Google Scholar
• Kapoor R, Kohli A, Sidharthan S. All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014;60:321
   Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21
   PubMed Web of Science ®Google Scholar
• Coppola N, Martini S, Pisaturo M, et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol 2015;4:1-12
   PubMedGoogle Scholar
• Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Jama 2014;312:353-61
   PubMed Web of Science ®Google Scholar
• Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It’s Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015;9. [Epub ahead of print]
   Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV. Presented at Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; 2015
   Google Scholar
• Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7
   PubMed Web of Science ®Google Scholar
• EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148:100-7
   PubMed Web of Science ®Google Scholar
• Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96
   PubMed Web of Science ®Google Scholar
• Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108-17
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015;15:00682-4
   Google Scholar
• Recommendations for Testing, Managing, and Treating Hepatitis C. Guidelines from AASLD/IDSA/IAS–USA. Available from: www.HCVguidelines.org [Last accessed 31 August 2015]
   Google Scholar
• Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with hcv genotype 1 infection. JAMA 2015;313:1728-35
   PubMed Web of Science ®Google Scholar
• In brief: severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther 2015;57:58
   PubMed Web of Science ®Google Scholar
• Jensen DM, O’Leary JG, Pockros PJ. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort act). Hepatology 2014;60:219
   Web of Science ®Google Scholar
• Dieterich D, Bacon BR, Flamm SL. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014;60:220
   Web of Science ®Google Scholar
• deLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014;20:315-21
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62(1 Suppl):006
   PubMedGoogle Scholar
• Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010;30:1259-69
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9
   PubMed Web of Science ®Google Scholar
• Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
   PubMed Web of Science ®Google Scholar
• Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med 2014;6:25-33
   PubMedGoogle Scholar
• Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92
   PubMed Web of Science ®Google Scholar
• McCarthy M. New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US. BMJ 2015;350:2055
   Web of Science ®Google Scholar
• Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS ONE 2015;10:e0126984
   PubMed Web of Science ®Google Scholar
• Reiberger T. Chronic hepatitis C: treat everyone now or stratify by disease? Minerva Gastroenterol Dietol 2015;61:11-19
   PubMedGoogle Scholar
• Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-23
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection. Gastroenterology 2015; Epub ahead of print
   Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-35
   PubMed Web of Science ®Google Scholar
• Esmat GE, Shiha G, Omar RF, et al. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston (MA), USA; 2014
   Google Scholar
• Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks with HCV genotype 3 or 6 infection. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA, USA; 2014
   Google Scholar